ReviewDermatology and therapy2020
Vitiligo, From Physiopathology to Emerging Treatments: A Review.
Review in Dermatology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Regulatory T Cell Dysregulation in Vitiligo: A Meta-Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives.International journal of dermatology · 2025Pooled it
- Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta-Analysis.Clinical pharmacology and therapeutics · 2025Pooled it
- Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.JAMA dermatology · 2025Trial
- Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo.Archives of dermatological research · 2024Trial
- [Association of vitiligo with endocrine autoimmune diseases: literature review].Problemy endokrinologii · 2026Review
- Association of Serum Interleukin-17 Levels With Vitiligo: A Pilot Cross-Sectional Comparative Study.Cureus · 2026Article
- Assessment of Narrowband Ultraviolet B Phototherapy Practices among Indian Dermatologists for Vitiligo.Indian dermatology online journal · 2026Article
- Epidemiology and Comorbidity of Vitiligo in Germany: A Claims Data Analysis.Acta dermato-venereologica · 2026Article
- Efficacy and Safety of Small Molecule Inhibitor Therapies for Vitiligo: A Systematic Review.Health science reports · 2026Review
- The role of JAK3 and TEC family kinases in vitiligo pathogenesis.Frontiers in immunology · 2026Review
- Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin.Science advances · 2025Article
- Clinical patterns of vitiligo in Japan: A descriptive study using the JMDC claims database.The Journal of dermatology · 2025Article
- Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Treatment Advances in Vitiligo: An Updated Review.Dermatology practical & conceptual · 2025Review
- Dietary Interventions, Supplements, and Plant-Derived Compounds for Adjunct Vitiligo Management: A Review of the Literature.Nutrients · 2025Review
- Comorbidities Associated with Vitiligo: Results from the EpiChron Cohort.Journal of clinical medicine · 2025Article
- Exploring the influence of gut microbiota metabolites on vitiligo through the gut-skin axis.Frontiers in microbiology · 2025Review
- The Anti-Vitiligo Effects of Feshurin In Vitro fromPharmaceuticals (Basel, Switzerland) · 2024Article
- Analysis of granulysin expression in vitiligo and halo-nevus.Scientific reports · 2024Article
- Identifying the genetic association between common rheumatic diseases and vitiligo.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is a chronic inflammatory skin disease leading to the loss of epidermal melanocytes. To date, treatment options for vitiligo patients are limited, lack sustained efficacy, and are mainly based on off-label use of immunosuppressive agents, such as systemic or topical steroids or topical calcineurin inhibitors, in association with the use of ultraviolet light. However, recent insights into the understanding of the immune pathogenesis of the disease have led to the identification of several therapeutic targets and the development of targeted therapies that are now being tested in clinical trials. In this review, based on the physiopathology of the disease, we summarize emerging targets that could be developed for the treatment of vitiligo and discuss recent and ongoing developments of drugs for the management of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.